Anika Therapeutics (NASDAQ:ANIK), Inc. is a life sciences company specializing in the development and commercialization of hyaluronic acid–based therapeutic products. The company focuses on orthobiologics and medical devices designed to support joint health, tissue repair and surgical applications. Anika’s proprietary hyaluronan technology serves as the foundation for products aimed at alleviating pain associated with osteoarthritis and enhancing healing in musculoskeletal and ophthalmic surgeries.
The company’s core product portfolio includes injectable viscosupplements such as Monovisc® and Orthovisc®, which are indicated for the relief of knee osteoarthritis pain, as well as Euflexxa®, approved for osteoarthritis of the knee in various international markets. Beyond viscosupplementation, Anika has expanded into adjacent areas with products for wound repair, surgical adhesion prevention and dermatological applications, leveraging its hyaluronan platform to address diverse clinical needs.
Founded in 1992 and headquartered in Bedford, Massachusetts, Anika maintains a global presence through direct subsidiaries and a network of distributors across North America, Europe and Asia Pacific. Since its public offering, the company has invested in manufacturing scale-up and research collaborations to drive innovation in biomaterials and extend its market reach into new therapeutic segments.
Leadership at Anika is headed by President and Chief Executive Officer Nam Rhee, under whose tenure the company has pursued strategic partnerships, product lifecycle extensions and pipeline development. Anika’s management team combines expertise in biotechnology, regulatory affairs and commercial operations to support ongoing growth and shareholder value creation.
